Giulia Pasqual, from the Department of Surgical, Oncological and Gastroenterological Sciences at the University of Padua, has been awarded for her innovative technology on the immune system. Her research, which systematically associates T-cell receptors with their targets, has potential applications in the treatment of cancer and autoimmune diseases.

The Executive Agency of the European Research Council (ERCEA) has announced the 136 Principal Investigators (PIs) selected in the latest ERC Proof of Concept 2025 call. This program supports excellent PIs who have already received an ERC grant, providing them with €150,000 to explore the commercial and social potential of their scientific ideas.

Giulia Pasqual won with her project CLIN-TCR, one of the 24 Italian projects selected. Her work aims to demonstrate the clinical value of the technology by applying it to cancer and autoimmune diseases, identifying specific T-cell receptors that recognize tumor antigens and components of the body in autoimmune diseases. "Understanding which receptors recognize which targets is crucial for developing more accurate diagnostic tools, personalized therapies, and new vaccines," stated Giulia Pasqual. Her innovative technology, already validated on a small scale, is protected by a patent application.

By generating and validating large sets of clinically relevant data, the project could provide new biomarkers and new opportunities for the development of immune-based therapies. In parallel, intellectual property protection will be strengthened, and a strategy for future commercial exploitation will be defined. Overall, the project can open new perspectives for precision medicine and accelerate the development of next-generation immunotherapies and therapeutic vaccines.

In 2025, 879 projects were submitted to the Commission, of which 300 were funded. Italy ranked third in terms of the number of grants obtained, with 31 grants.
"The discoveries funded by the ERC are more than just academic advancements," commented Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. "They lay the foundations for future innovation ecosystems across Europe."

Giulia Pasqual, from the Department of Surgical, Oncological and Gastroenterological Sciences at the University of Padua, has been awarded for her innovative technology on the immune system. Her research, which systematically associates T-cell receptors with their targets, has potential applications in the treatment of cancer and autoimmune diseases.

The Executive Agency of the European Research Council (ERCEA) has announced the 136 Principal Investigators (PIs) selected in the latest ERC Proof of Concept 2025 call. This program supports excellent PIs who have already received an ERC grant, providing them with €150,000 to explore the commercial and social potential of their scientific ideas.

Giulia Pasqual won with her project CLIN-TCR, one of the 24 Italian projects selected. Her work aims to demonstrate the clinical value of the technology by applying it to cancer and autoimmune diseases, identifying specific T-cell receptors that recognize tumor antigens and components of the body in autoimmune diseases. "Understanding which receptors recognize which targets is crucial for developing more accurate diagnostic tools, personalized therapies, and new vaccines," stated Giulia Pasqual. Her innovative technology, already validated on a small scale, is protected by a patent application.

By generating and validating large sets of clinically relevant data, the project could provide new biomarkers and new opportunities for the development of immune-based therapies. In parallel, intellectual property protection will be strengthened, and a strategy for future commercial exploitation will be defined. Overall, the project can open new perspectives for precision medicine and accelerate the development of next-generation immunotherapies and therapeutic vaccines.

In 2025, 879 projects were submitted to the Commission, of which 300 were funded. Italy ranked third in terms of the number of grants obtained, with 31 grants.
"The discoveries funded by the ERC are more than just academic advancements," commented Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. "They lay the foundations for future innovation ecosystems across Europe."

Giulia Pasqual, from the Department of Surgical, Oncological and Gastroenterological Sciences at the University of Padua, has been awarded for her innovative technology on the immune system. Her research, which systematically associates T-cell receptors with their targets, has potential applications in the treatment of cancer and autoimmune diseases.

The Executive Agency of the European Research Council (ERCEA) has announced the 136 Principal Investigators (PIs) selected in the latest ERC Proof of Concept 2025 call. This program supports excellent PIs who have already received an ERC grant, providing them with €150,000 to explore the commercial and social potential of their scientific ideas.

Giulia Pasqual won with her project CLIN-TCR, one of the 24 Italian projects selected. Her work aims to demonstrate the clinical value of the technology by applying it to cancer and autoimmune diseases, identifying specific T-cell receptors that recognize tumor antigens and components of the body in autoimmune diseases. "Understanding which receptors recognize which targets is crucial for developing more accurate diagnostic tools, personalized therapies, and new vaccines," stated Giulia Pasqual. Her innovative technology, already validated on a small scale, is protected by a patent application.

By generating and validating large sets of clinically relevant data, the project could provide new biomarkers and new opportunities for the development of immune-based therapies. In parallel, intellectual property protection will be strengthened, and a strategy for future commercial exploitation will be defined. Overall, the project can open new perspectives for precision medicine and accelerate the development of next-generation immunotherapies and therapeutic vaccines.

In 2025, 879 projects were submitted to the Commission, of which 300 were funded. Italy ranked third in terms of the number of grants obtained, with 31 grants.
"The discoveries funded by the ERC are more than just academic advancements," commented Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. "They lay the foundations for future innovation ecosystems across Europe."

Giulia Pasqual, from the Department of Surgical, Oncological and Gastroenterological Sciences at the University of Padua, has been awarded for her innovative technology on the immune system. Her research, which systematically associates T-cell receptors with their targets, has potential applications in the treatment of cancer and autoimmune diseases.

The Executive Agency of the European Research Council (ERCEA) has announced the 136 Principal Investigators (PIs) selected in the latest ERC Proof of Concept 2025 call. This program supports excellent PIs who have already received an ERC grant, providing them with €150,000 to explore the commercial and social potential of their scientific ideas.

Giulia Pasqual won with her project CLIN-TCR, one of the 24 Italian projects selected. Her work aims to demonstrate the clinical value of the technology by applying it to cancer and autoimmune diseases, identifying specific T-cell receptors that recognize tumor antigens and components of the body in autoimmune diseases. "Understanding which receptors recognize which targets is crucial for developing more accurate diagnostic tools, personalized therapies, and new vaccines," stated Giulia Pasqual. Her innovative technology, already validated on a small scale, is protected by a patent application.

By generating and validating large sets of clinically relevant data, the project could provide new biomarkers and new opportunities for the development of immune-based therapies. In parallel, intellectual property protection will be strengthened, and a strategy for future commercial exploitation will be defined. Overall, the project can open new perspectives for precision medicine and accelerate the development of next-generation immunotherapies and therapeutic vaccines.

In 2025, 879 projects were submitted to the Commission, of which 300 were funded. Italy ranked third in terms of the number of grants obtained, with 31 grants.
"The discoveries funded by the ERC are more than just academic advancements," commented Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. "They lay the foundations for future innovation ecosystems across Europe."

Giulia Pasqual, from the Department of Surgical, Oncological and Gastroenterological Sciences at the University of Padua, has been awarded for her innovative technology on the immune system. Her research, which systematically associates T-cell receptors with their targets, has potential applications in the treatment of cancer and autoimmune diseases.

Giulia Pasqual, from the Department of Surgical, Oncological and Gastroenterological Sciences at the University of Padua, has been awarded for her innovative technology on the immune system. Her research, which systematically associates T-cell receptors with their targets, has potential applications in the treatment of cancer and autoimmune diseases.

The Executive Agency of the European Research Council (ERCEA) has announced the 136 Principal Investigators (PIs) selected in the latest ERC Proof of Concept 2025 call. This program supports excellent PIs who have already received an ERC grant, providing them with €150,000 to explore the commercial and social potential of their scientific ideas.

Giulia Pasqual won with her project CLIN-TCR, one of the 24 Italian projects selected. Her work aims to demonstrate the clinical value of the technology by applying it to cancer and autoimmune diseases, identifying specific T-cell receptors that recognize tumor antigens and components of the body in autoimmune diseases. "Understanding which receptors recognize which targets is crucial for developing more accurate diagnostic tools, personalized therapies, and new vaccines," stated Giulia Pasqual. Her innovative technology, already validated on a small scale, is protected by a patent application.

By generating and validating large sets of clinically relevant data, the project could provide new biomarkers and new opportunities for the development of immune-based therapies. In parallel, intellectual property protection will be strengthened, and a strategy for future commercial exploitation will be defined. Overall, the project can open new perspectives for precision medicine and accelerate the development of next-generation immunotherapies and therapeutic vaccines.

In 2025, 879 projects were submitted to the Commission, of which 300 were funded. Italy ranked third in terms of the number of grants obtained, with 31 grants.
"The discoveries funded by the ERC are more than just academic advancements," commented Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. "They lay the foundations for future innovation ecosystems across Europe."

Giulia Pasqual, from the Department of Surgical, Oncological and Gastroenterological Sciences at the University of Padua, has been awarded for her innovative technology on the immune system. Her research, which systematically associates T-cell receptors with their targets, has potential applications in the treatment of cancer and autoimmune diseases.

The Executive Agency of the European Research Council (ERCEA) has announced the 136 Principal Investigators (PIs) selected in the latest ERC Proof of Concept 2025 call. This program supports excellent PIs who have already received an ERC grant, providing them with €150,000 to explore the commercial and social potential of their scientific ideas.

Giulia Pasqual won with her project CLIN-TCR, one of the 24 Italian projects selected. Her work aims to demonstrate the clinical value of the technology by applying it to cancer and autoimmune diseases, identifying specific T-cell receptors that recognize tumor antigens and components of the body in autoimmune diseases. "Understanding which receptors recognize which targets is crucial for developing more accurate diagnostic tools, personalized therapies, and new vaccines," stated Giulia Pasqual. Her innovative technology, already validated on a small scale, is protected by a patent application.

By generating and validating large sets of clinically relevant data, the project could provide new biomarkers and new opportunities for the development of immune-based therapies. In parallel, intellectual property protection will be strengthened, and a strategy for future commercial exploitation will be defined. Overall, the project can open new perspectives for precision medicine and accelerate the development of next-generation immunotherapies and therapeutic vaccines.

In 2025, 879 projects were submitted to the Commission, of which 300 were funded. Italy ranked third in terms of the number of grants obtained, with 31 grants.
"The discoveries funded by the ERC are more than just academic advancements," commented Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. "They lay the foundations for future innovation ecosystems across Europe."

Giulia Pasqual, from the Department of Surgical, Oncological and Gastroenterological Sciences at the University of Padua, has been awarded for her innovative technology on the immune system. Her research, which systematically associates T-cell receptors with their targets, has potential applications in the treatment of cancer and autoimmune diseases.

The Executive Agency of the European Research Council (ERCEA) has announced the 136 Principal Investigators (PIs) selected in the latest ERC Proof of Concept 2025 call. This program supports excellent PIs who have already received an ERC grant, providing them with €150,000 to explore the commercial and social potential of their scientific ideas.

Giulia Pasqual won with her project CLIN-TCR, one of the 24 Italian projects selected. Her work aims to demonstrate the clinical value of the technology by applying it to cancer and autoimmune diseases, identifying specific T-cell receptors that recognize tumor antigens and components of the body in autoimmune diseases. "Understanding which receptors recognize which targets is crucial for developing more accurate diagnostic tools, personalized therapies, and new vaccines," stated Giulia Pasqual. Her innovative technology, already validated on a small scale, is protected by a patent application.

By generating and validating large sets of clinically relevant data, the project could provide new biomarkers and new opportunities for the development of immune-based therapies. In parallel, intellectual property protection will be strengthened, and a strategy for future commercial exploitation will be defined. Overall, the project can open new perspectives for precision medicine and accelerate the development of next-generation immunotherapies and therapeutic vaccines.

In 2025, 879 projects were submitted to the Commission, of which 300 were funded. Italy ranked third in terms of the number of grants obtained, with 31 grants.
"The discoveries funded by the ERC are more than just academic advancements," commented Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. "They lay the foundations for future innovation ecosystems across Europe."

Giulia Pasqual, from the Department of Surgical, Oncological and Gastroenterological Sciences at the University of Padua, has been awarded for her innovative technology on the immune system. Her research, which systematically associates T-cell receptors with their targets, has potential applications in the treatment of cancer and autoimmune diseases.

The Executive Agency of the European Research Council (ERCEA) has announced the 136 Principal Investigators (PIs) selected in the latest ERC Proof of Concept 2025 call. This program supports excellent PIs who have already received an ERC grant, providing them with €150,000 to explore the commercial and social potential of their scientific ideas.

Giulia Pasqual won with her project CLIN-TCR, one of the 24 Italian projects selected. Her work aims to demonstrate the clinical value of the technology by applying it to cancer and autoimmune diseases, identifying specific T-cell receptors that recognize tumor antigens and components of the body in autoimmune diseases. "Understanding which receptors recognize which targets is crucial for developing more accurate diagnostic tools, personalized therapies, and new vaccines," stated Giulia Pasqual. Her innovative technology, already validated on a small scale, is protected by a patent application.

By generating and validating large sets of clinically relevant data, the project could provide new biomarkers and new opportunities for the development of immune-based therapies. In parallel, intellectual property protection will be strengthened, and a strategy for future commercial exploitation will be defined. Overall, the project can open new perspectives for precision medicine and accelerate the development of next-generation immunotherapies and therapeutic vaccines.

In 2025, 879 projects were submitted to the Commission, of which 300 were funded. Italy ranked third in terms of the number of grants obtained, with 31 grants.
"The discoveries funded by the ERC are more than just academic advancements," commented Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. "They lay the foundations for future innovation ecosystems across Europe."

Giulia Pasqual, from the Department of Surgical, Oncological and Gastroenterological Sciences at the University of Padua, has been awarded for her innovative technology on the immune system. Her research, which systematically associates T-cell receptors with their targets, has potential applications in the treatment of cancer and autoimmune diseases.

The Executive Agency of the European Research Council (ERCEA) has announced the 136 Principal Investigators (PIs) selected in the latest ERC Proof of Concept 2025 call. This program supports excellent PIs who have already received an ERC grant, providing them with €150,000 to explore the commercial and social potential of their scientific ideas.

Giulia Pasqual won with her project CLIN-TCR, one of the 24 Italian projects selected. Her work aims to demonstrate the clinical value of the technology by applying it to cancer and autoimmune diseases, identifying specific T-cell receptors that recognize tumor antigens and components of the body in autoimmune diseases. "Understanding which receptors recognize which targets is crucial for developing more accurate diagnostic tools, personalized therapies, and new vaccines," stated Giulia Pasqual. Her innovative technology, already validated on a small scale, is protected by a patent application.

By generating and validating large sets of clinically relevant data, the project could provide new biomarkers and new opportunities for the development of immune-based therapies. In parallel, intellectual property protection will be strengthened, and a strategy for future commercial exploitation will be defined. Overall, the project can open new perspectives for precision medicine and accelerate the development of next-generation immunotherapies and therapeutic vaccines.

In 2025, 879 projects were submitted to the Commission, of which 300 were funded. Italy ranked third in terms of the number of grants obtained, with 31 grants.
"The discoveries funded by the ERC are more than just academic advancements," commented Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. "They lay the foundations for future innovation ecosystems across Europe."

Giulia Pasqual, from the Department of Surgical, Oncological and Gastroenterological Sciences at the University of Padua, has been awarded for her innovative technology on the immune system. Her research, which systematically associates T-cell receptors with their targets, has potential applications in the treatment of cancer and autoimmune diseases.

The Executive Agency of the European Research Council (ERCEA) has announced the 136 Principal Investigators (PIs) selected in the latest ERC Proof of Concept 2025 call. This program supports excellent PIs who have already received an ERC grant, providing them with €150,000 to explore the commercial and social potential of their scientific ideas.

Giulia Pasqual won with her project CLIN-TCR, one of the 24 Italian projects selected. Her work aims to demonstrate the clinical value of the technology by applying it to cancer and autoimmune diseases, identifying specific T-cell receptors that recognize tumor antigens and components of the body in autoimmune diseases. "Understanding which receptors recognize which targets is crucial for developing more accurate diagnostic tools, personalized therapies, and new vaccines," stated Giulia Pasqual. Her innovative technology, already validated on a small scale, is protected by a patent application.

By generating and validating large sets of clinically relevant data, the project could provide new biomarkers and new opportunities for the development of immune-based therapies. In parallel, intellectual property protection will be strengthened, and a strategy for future commercial exploitation will be defined. Overall, the project can open new perspectives for precision medicine and accelerate the development of next-generation immunotherapies and therapeutic vaccines.

In 2025, 879 projects were submitted to the Commission, of which 300 were funded. Italy ranked third in terms of the number of grants obtained, with 31 grants.
"The discoveries funded by the ERC are more than just academic advancements," commented Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. "They lay the foundations for future innovation ecosystems across Europe."

Giulia Pasqual, del Dipartimento di Scienze chirurgiche, oncologiche e gastroenterologiche dell'Università di Padova, è stata premiata per la sua tecnologia innovativa sul sistema immunitario. La sua ricerca, che permette di associare sistematicamente i recettori dei linfociti T ai loro bersagli, ha potenziali applicazioni nel trattamento del cancro e delle malattie autoimmuni.

L'Agenzia Esecutiva dello European Research Council (ERCEA) ha annunciato i 136 Principal Investigator (PI) selezionati nell'ambito dell'ultima call ERC Proof of Concept 2025. Questo programma supporta PI eccellenti che hanno già ricevuto una sovvenzione ERC, fornendo loro un finanziamento di 150 mila euro per esplorare il potenziale commerciale e sociale delle loro idee scientifiche.

Giulia Pasqual ha vinto con il progetto CLIN-TCR, uno dei 24 progetti italiani selezionati. Il suo lavoro mira a dimostrare il valore clinico della tecnologia applicandola al cancro e alle malattie autoimmuni, identificando recettori specifici dei linfociti T che riconoscono antigeni tumorali e componenti dell'organismo nelle malattie autoimmuni. "Comprendere quali recettori riconoscono quali bersagli è fondamentale per sviluppare strumenti diagnostici più accurati, terapie personalizzate e nuovi vaccini", ha dichiarato Giulia Pasqual. La sua tecnologia innovativa, già validata su piccola scala, è protetta da una domanda di brevetto.

Generando e validando ampi insiemi di dati di rilevanza clinica, il progetto potrà fornire nuovi biomarcatori e nuove opportunità per lo sviluppo di terapie basate sul sistema immunitario. E parallelamente, verrà rafforzata la protezione della proprietà intellettuale e definita una strategia per un futuro sfruttamento commerciale. Nel complesso, il progetto può aprire nuove prospettive per la medicina di precisione e accelerare lo sviluppo di immunoterapie e vaccini terapeutici di nuova generazione.

Nel 2025, sono stati presentati 879 progetti alla Commissione, di cui 300 sono stati finanziati. L'Italia si è classificata al terzo posto per numero di finanziamenti ottenuti, con 31 grant.
"Le scoperte finanziate dall'ERC sono più di semplici progressi accademici", ha commentato Ekaterina Zaharieva, commissaria europea per le Startup, la Ricerca e l'Innovazione. "Costituiscono le fondamenta dei futuri ecosistemi dell'innovazione in tutta Europa".

Giulia Pasqual, del Dipartimento di Scienze chirurgiche, oncologiche e gastroenterologiche dell'Università di Padova, è stata premiata per la sua tecnologia innovativa sul sistema immunitario. La sua ricerca, che permette di associare sistematicamente i recettori dei linfociti T ai loro bersagli, ha potenziali applicazioni nel trattamento del cancro e delle malattie autoimmuni.

L'Agenzia Esecutiva dello European Research Council (ERCEA) ha annunciato i 136 Principal Investigator (PI) selezionati nell'ambito dell'ultima call ERC Proof of Concept 2025. Questo programma supporta PI eccellenti che hanno già ricevuto una sovvenzione ERC, fornendo loro un finanziamento di 150 mila euro per esplorare il potenziale commerciale e sociale delle loro idee scientifiche.

Giulia Pasqual ha vinto con il progetto CLIN-TCR, uno dei 24 progetti italiani selezionati. Il suo lavoro mira a dimostrare il valore clinico della tecnologia applicandola al cancro e alle malattie autoimmuni, identificando recettori specifici dei linfociti T che riconoscono antigeni tumorali e componenti dell'organismo nelle malattie autoimmuni. "Comprendere quali recettori riconoscono quali bersagli è fondamentale per sviluppare strumenti diagnostici più accurati, terapie personalizzate e nuovi vaccini", ha dichiarato Giulia Pasqual. La sua tecnologia innovativa, già validata su piccola scala, è protetta da una domanda di brevetto.

Generando e validando ampi insiemi di dati di rilevanza clinica, il progetto potrà fornire nuovi biomarcatori e nuove opportunità per lo sviluppo di terapie basate sul sistema immunitario. E parallelamente, verrà rafforzata la protezione della proprietà intellettuale e definita una strategia per un futuro sfruttamento commerciale. Nel complesso, il progetto può aprire nuove prospettive per la medicina di precisione e accelerare lo sviluppo di immunoterapie e vaccini terapeutici di nuova generazione.

Nel 2025, sono stati presentati 879 progetti alla Commissione, di cui 300 sono stati finanziati. L'Italia si è classificata al terzo posto per numero di finanziamenti ottenuti, con 31 grant.
"Le scoperte finanziate dall'ERC sono più di semplici progressi accademici", ha commentato Ekaterina Zaharieva, commissaria europea per le Startup, la Ricerca e l'Innovazione. "Costituiscono le fondamenta dei futuri ecosistemi dell'innovazione in tutta Europa".

Giulia Pasqual, del Dipartimento di Scienze chirurgiche, oncologiche e gastroenterologiche dell'Università di Padova, è stata premiata per la sua tecnologia innovativa sul sistema immunitario. La sua ricerca, che permette di associare sistematicamente i recettori dei linfociti T ai loro bersagli, ha potenziali applicazioni nel trattamento del cancro e delle malattie autoimmuni.

L'Agenzia Esecutiva dello European Research Council (ERCEA) ha annunciato i 136 Principal Investigator (PI) selezionati nell'ambito dell'ultima call ERC Proof of Concept 2025. Questo programma supporta PI eccellenti che hanno già ricevuto una sovvenzione ERC, fornendo loro un finanziamento di 150 mila euro per esplorare il potenziale commerciale e sociale delle loro idee scientifiche.

Giulia Pasqual ha vinto con il progetto CLIN-TCR, uno dei 24 progetti italiani selezionati. Il suo lavoro mira a dimostrare il valore clinico della tecnologia applicandola al cancro e alle malattie autoimmuni, identificando recettori specifici dei linfociti T che riconoscono antigeni tumorali e componenti dell'organismo nelle malattie autoimmuni. "Comprendere quali recettori riconoscono quali bersagli è fondamentale per sviluppare strumenti diagnostici più accurati, terapie personalizzate e nuovi vaccini", ha dichiarato Giulia Pasqual. La sua tecnologia innovativa, già validata su piccola scala, è protetta da una domanda di brevetto.

Generando e validando ampi insiemi di dati di rilevanza clinica, il progetto potrà fornire nuovi biomarcatori e nuove opportunità per lo sviluppo di terapie basate sul sistema immunitario. E parallelamente, verrà rafforzata la protezione della proprietà intellettuale e definita una strategia per un futuro sfruttamento commerciale. Nel complesso, il progetto può aprire nuove prospettive per la medicina di precisione e accelerare lo sviluppo di immunoterapie e vaccini terapeutici di nuova generazione.

Nel 2025, sono stati presentati 879 progetti alla Commissione, di cui 300 sono stati finanziati. L'Italia si è classificata al terzo posto per numero di finanziamenti ottenuti, con 31 grant.
"Le scoperte finanziate dall'ERC sono più di semplici progressi accademici", ha commentato Ekaterina Zaharieva, commissaria europea per le Startup, la Ricerca e l'Innovazione. "Costituiscono le fondamenta dei futuri ecosistemi dell'innovazione in tutta Europa".

Giulia Pasqual, del Dipartimento di Scienze chirurgiche, oncologiche e gastroenterologiche dell'Università di Padova, è stata premiata per la sua tecnologia innovativa sul sistema immunitario. La sua ricerca, che permette di associare sistematicamente i recettori dei linfociti T ai loro bersagli, ha potenziali applicazioni nel trattamento del cancro e delle malattie autoimmuni.

L'Agenzia Esecutiva dello European Research Council (ERCEA) ha annunciato i 136 Principal Investigator (PI) selezionati nell'ambito dell'ultima call ERC Proof of Concept 2025. Questo programma supporta PI eccellenti che hanno già ricevuto una sovvenzione ERC, fornendo loro un finanziamento di 150 mila euro per esplorare il potenziale commerciale e sociale delle loro idee scientifiche.

Giulia Pasqual ha vinto con il progetto CLIN-TCR, uno dei 24 progetti italiani selezionati. Il suo lavoro mira a dimostrare il valore clinico della tecnologia applicandola al cancro e alle malattie autoimmuni, identificando recettori specifici dei linfociti T che riconoscono antigeni tumorali e componenti dell'organismo nelle malattie autoimmuni. "Comprendere quali recettori riconoscono quali bersagli è fondamentale per sviluppare strumenti diagnostici più accurati, terapie personalizzate e nuovi vaccini", ha dichiarato Giulia Pasqual. La sua tecnologia innovativa, già validata su piccola scala, è protetta da una domanda di brevetto.

Generando e validando ampi insiemi di dati di rilevanza clinica, il progetto potrà fornire nuovi biomarcatori e nuove opportunità per lo sviluppo di terapie basate sul sistema immunitario. E parallelamente, verrà rafforzata la protezione della proprietà intellettuale e definita una strategia per un futuro sfruttamento commerciale. Nel complesso, il progetto può aprire nuove prospettive per la medicina di precisione e accelerare lo sviluppo di immunoterapie e vaccini terapeutici di nuova generazione.

Nel 2025, sono stati presentati 879 progetti alla Commissione, di cui 300 sono stati finanziati. L'Italia si è classificata al terzo posto per numero di finanziamenti ottenuti, con 31 grant.
"Le scoperte finanziate dall'ERC sono più di semplici progressi accademici", ha commentato Ekaterina Zaharieva, commissaria europea per le Startup, la Ricerca e l'Innovazione. "Costituiscono le fondamenta dei futuri ecosistemi dell'innovazione in tutta Europa".

Giulia Pasqual, del Dipartimento di Scienze chirurgiche, oncologiche e gastroenterologiche dell'Università di Padova, è stata premiata per la sua tecnologia innovativa sul sistema immunitario. La sua ricerca, che permette di associare sistematicamente i recettori dei linfociti T ai loro bersagli, ha potenziali applicazioni nel trattamento del cancro e delle malattie autoimmuni.

Giulia Pasqual, del Dipartimento di Scienze chirurgiche, oncologiche e gastroenterologiche dell'Università di Padova, è stata premiata per la sua tecnologia innovativa sul sistema immunitario. La sua ricerca, che permette di associare sistematicamente i recettori dei linfociti T ai loro bersagli, ha potenziali applicazioni nel trattamento del cancro e delle malattie autoimmuni.

L'Agenzia Esecutiva dello European Research Council (ERCEA) ha annunciato i 136 Principal Investigator (PI) selezionati nell'ambito dell'ultima call ERC Proof of Concept 2025. Questo programma supporta PI eccellenti che hanno già ricevuto una sovvenzione ERC, fornendo loro un finanziamento di 150 mila euro per esplorare il potenziale commerciale e sociale delle loro idee scientifiche.

Giulia Pasqual ha vinto con il progetto CLIN-TCR, uno dei 24 progetti italiani selezionati. Il suo lavoro mira a dimostrare il valore clinico della tecnologia applicandola al cancro e alle malattie autoimmuni, identificando recettori specifici dei linfociti T che riconoscono antigeni tumorali e componenti dell'organismo nelle malattie autoimmuni. "Comprendere quali recettori riconoscono quali bersagli è fondamentale per sviluppare strumenti diagnostici più accurati, terapie personalizzate e nuovi vaccini", ha dichiarato Giulia Pasqual. La sua tecnologia innovativa, già validata su piccola scala, è protetta da una domanda di brevetto.

Generando e validando ampi insiemi di dati di rilevanza clinica, il progetto potrà fornire nuovi biomarcatori e nuove opportunità per lo sviluppo di terapie basate sul sistema immunitario. E parallelamente, verrà rafforzata la protezione della proprietà intellettuale e definita una strategia per un futuro sfruttamento commerciale. Nel complesso, il progetto può aprire nuove prospettive per la medicina di precisione e accelerare lo sviluppo di immunoterapie e vaccini terapeutici di nuova generazione.

Nel 2025, sono stati presentati 879 progetti alla Commissione, di cui 300 sono stati finanziati. L'Italia si è classificata al terzo posto per numero di finanziamenti ottenuti, con 31 grant.
"Le scoperte finanziate dall'ERC sono più di semplici progressi accademici", ha commentato Ekaterina Zaharieva, commissaria europea per le Startup, la Ricerca e l'Innovazione. "Costituiscono le fondamenta dei futuri ecosistemi dell'innovazione in tutta Europa".

Giulia Pasqual, del Dipartimento di Scienze chirurgiche, oncologiche e gastroenterologiche dell'Università di Padova, è stata premiata per la sua tecnologia innovativa sul sistema immunitario. La sua ricerca, che permette di associare sistematicamente i recettori dei linfociti T ai loro bersagli, ha potenziali applicazioni nel trattamento del cancro e delle malattie autoimmuni.

L'Agenzia Esecutiva dello European Research Council (ERCEA) ha annunciato i 136 Principal Investigator (PI) selezionati nell'ambito dell'ultima call ERC Proof of Concept 2025. Questo programma supporta PI eccellenti che hanno già ricevuto una sovvenzione ERC, fornendo loro un finanziamento di 150 mila euro per esplorare il potenziale commerciale e sociale delle loro idee scientifiche.

Giulia Pasqual ha vinto con il progetto CLIN-TCR, uno dei 24 progetti italiani selezionati. Il suo lavoro mira a dimostrare il valore clinico della tecnologia applicandola al cancro e alle malattie autoimmuni, identificando recettori specifici dei linfociti T che riconoscono antigeni tumorali e componenti dell'organismo nelle malattie autoimmuni. "Comprendere quali recettori riconoscono quali bersagli è fondamentale per sviluppare strumenti diagnostici più accurati, terapie personalizzate e nuovi vaccini", ha dichiarato Giulia Pasqual. La sua tecnologia innovativa, già validata su piccola scala, è protetta da una domanda di brevetto.

Generando e validando ampi insiemi di dati di rilevanza clinica, il progetto potrà fornire nuovi biomarcatori e nuove opportunità per lo sviluppo di terapie basate sul sistema immunitario. E parallelamente, verrà rafforzata la protezione della proprietà intellettuale e definita una strategia per un futuro sfruttamento commerciale. Nel complesso, il progetto può aprire nuove prospettive per la medicina di precisione e accelerare lo sviluppo di immunoterapie e vaccini terapeutici di nuova generazione.

Nel 2025, sono stati presentati 879 progetti alla Commissione, di cui 300 sono stati finanziati. L'Italia si è classificata al terzo posto per numero di finanziamenti ottenuti, con 31 grant.
"Le scoperte finanziate dall'ERC sono più di semplici progressi accademici", ha commentato Ekaterina Zaharieva, commissaria europea per le Startup, la Ricerca e l'Innovazione. "Costituiscono le fondamenta dei futuri ecosistemi dell'innovazione in tutta Europa".

Giulia Pasqual, del Dipartimento di Scienze chirurgiche, oncologiche e gastroenterologiche dell'Università di Padova, è stata premiata per la sua tecnologia innovativa sul sistema immunitario. La sua ricerca, che permette di associare sistematicamente i recettori dei linfociti T ai loro bersagli, ha potenziali applicazioni nel trattamento del cancro e delle malattie autoimmuni.

L'Agenzia Esecutiva dello European Research Council (ERCEA) ha annunciato i 136 Principal Investigator (PI) selezionati nell'ambito dell'ultima call ERC Proof of Concept 2025. Questo programma supporta PI eccellenti che hanno già ricevuto una sovvenzione ERC, fornendo loro un finanziamento di 150 mila euro per esplorare il potenziale commerciale e sociale delle loro idee scientifiche.

Giulia Pasqual ha vinto con il progetto CLIN-TCR, uno dei 24 progetti italiani selezionati. Il suo lavoro mira a dimostrare il valore clinico della tecnologia applicandola al cancro e alle malattie autoimmuni, identificando recettori specifici dei linfociti T che riconoscono antigeni tumorali e componenti dell'organismo nelle malattie autoimmuni. "Comprendere quali recettori riconoscono quali bersagli è fondamentale per sviluppare strumenti diagnostici più accurati, terapie personalizzate e nuovi vaccini", ha dichiarato Giulia Pasqual. La sua tecnologia innovativa, già validata su piccola scala, è protetta da una domanda di brevetto.

Generando e validando ampi insiemi di dati di rilevanza clinica, il progetto potrà fornire nuovi biomarcatori e nuove opportunità per lo sviluppo di terapie basate sul sistema immunitario. E parallelamente, verrà rafforzata la protezione della proprietà intellettuale e definita una strategia per un futuro sfruttamento commerciale. Nel complesso, il progetto può aprire nuove prospettive per la medicina di precisione e accelerare lo sviluppo di immunoterapie e vaccini terapeutici di nuova generazione.

Nel 2025, sono stati presentati 879 progetti alla Commissione, di cui 300 sono stati finanziati. L'Italia si è classificata al terzo posto per numero di finanziamenti ottenuti, con 31 grant.
"Le scoperte finanziate dall'ERC sono più di semplici progressi accademici", ha commentato Ekaterina Zaharieva, commissaria europea per le Startup, la Ricerca e l'Innovazione. "Costituiscono le fondamenta dei futuri ecosistemi dell'innovazione in tutta Europa".

Giulia Pasqual, del Dipartimento di Scienze chirurgiche, oncologiche e gastroenterologiche dell'Università di Padova, è stata premiata per la sua tecnologia innovativa sul sistema immunitario. La sua ricerca, che permette di associare sistematicamente i recettori dei linfociti T ai loro bersagli, ha potenziali applicazioni nel trattamento del cancro e delle malattie autoimmuni.

L'Agenzia Esecutiva dello European Research Council (ERCEA) ha annunciato i 136 Principal Investigator (PI) selezionati nell'ambito dell'ultima call ERC Proof of Concept 2025. Questo programma supporta PI eccellenti che hanno già ricevuto una sovvenzione ERC, fornendo loro un finanziamento di 150 mila euro per esplorare il potenziale commerciale e sociale delle loro idee scientifiche.

Giulia Pasqual ha vinto con il progetto CLIN-TCR, uno dei 24 progetti italiani selezionati. Il suo lavoro mira a dimostrare il valore clinico della tecnologia applicandola al cancro e alle malattie autoimmuni, identificando recettori specifici dei linfociti T che riconoscono antigeni tumorali e componenti dell'organismo nelle malattie autoimmuni. "Comprendere quali recettori riconoscono quali bersagli è fondamentale per sviluppare strumenti diagnostici più accurati, terapie personalizzate e nuovi vaccini", ha dichiarato Giulia Pasqual. La sua tecnologia innovativa, già validata su piccola scala, è protetta da una domanda di brevetto.

Generando e validando ampi insiemi di dati di rilevanza clinica, il progetto potrà fornire nuovi biomarcatori e nuove opportunità per lo sviluppo di terapie basate sul sistema immunitario. E parallelamente, verrà rafforzata la protezione della proprietà intellettuale e definita una strategia per un futuro sfruttamento commerciale. Nel complesso, il progetto può aprire nuove prospettive per la medicina di precisione e accelerare lo sviluppo di immunoterapie e vaccini terapeutici di nuova generazione.

Nel 2025, sono stati presentati 879 progetti alla Commissione, di cui 300 sono stati finanziati. L'Italia si è classificata al terzo posto per numero di finanziamenti ottenuti, con 31 grant.
"Le scoperte finanziate dall'ERC sono più di semplici progressi accademici", ha commentato Ekaterina Zaharieva, commissaria europea per le Startup, la Ricerca e l'Innovazione. "Costituiscono le fondamenta dei futuri ecosistemi dell'innovazione in tutta Europa".

Giulia Pasqual, del Dipartimento di Scienze chirurgiche, oncologiche e gastroenterologiche dell'Università di Padova, è stata premiata per la sua tecnologia innovativa sul sistema immunitario. La sua ricerca, che permette di associare sistematicamente i recettori dei linfociti T ai loro bersagli, ha potenziali applicazioni nel trattamento del cancro e delle malattie autoimmuni.

L'Agenzia Esecutiva dello European Research Council (ERCEA) ha annunciato i 136 Principal Investigator (PI) selezionati nell'ambito dell'ultima call ERC Proof of Concept 2025. Questo programma supporta PI eccellenti che hanno già ricevuto una sovvenzione ERC, fornendo loro un finanziamento di 150 mila euro per esplorare il potenziale commerciale e sociale delle loro idee scientifiche.

Giulia Pasqual ha vinto con il progetto CLIN-TCR, uno dei 24 progetti italiani selezionati. Il suo lavoro mira a dimostrare il valore clinico della tecnologia applicandola al cancro e alle malattie autoimmuni, identificando recettori specifici dei linfociti T che riconoscono antigeni tumorali e componenti dell'organismo nelle malattie autoimmuni. "Comprendere quali recettori riconoscono quali bersagli è fondamentale per sviluppare strumenti diagnostici più accurati, terapie personalizzate e nuovi vaccini", ha dichiarato Giulia Pasqual. La sua tecnologia innovativa, già validata su piccola scala, è protetta da una domanda di brevetto.

Generando e validando ampi insiemi di dati di rilevanza clinica, il progetto potrà fornire nuovi biomarcatori e nuove opportunità per lo sviluppo di terapie basate sul sistema immunitario. E parallelamente, verrà rafforzata la protezione della proprietà intellettuale e definita una strategia per un futuro sfruttamento commerciale. Nel complesso, il progetto può aprire nuove prospettive per la medicina di precisione e accelerare lo sviluppo di immunoterapie e vaccini terapeutici di nuova generazione.

Nel 2025, sono stati presentati 879 progetti alla Commissione, di cui 300 sono stati finanziati. L'Italia si è classificata al terzo posto per numero di finanziamenti ottenuti, con 31 grant.
"Le scoperte finanziate dall'ERC sono più di semplici progressi accademici", ha commentato Ekaterina Zaharieva, commissaria europea per le Startup, la Ricerca e l'Innovazione. "Costituiscono le fondamenta dei futuri ecosistemi dell'innovazione in tutta Europa".

Giulia Pasqual, del Dipartimento di Scienze chirurgiche, oncologiche e gastroenterologiche dell'Università di Padova, è stata premiata per la sua tecnologia innovativa sul sistema immunitario. La sua ricerca, che permette di associare sistematicamente i recettori dei linfociti T ai loro bersagli, ha potenziali applicazioni nel trattamento del cancro e delle malattie autoimmuni.

L'Agenzia Esecutiva dello European Research Council (ERCEA) ha annunciato i 136 Principal Investigator (PI) selezionati nell'ambito dell'ultima call ERC Proof of Concept 2025. Questo programma supporta PI eccellenti che hanno già ricevuto una sovvenzione ERC, fornendo loro un finanziamento di 150 mila euro per esplorare il potenziale commerciale e sociale delle loro idee scientifiche.

Giulia Pasqual ha vinto con il progetto CLIN-TCR, uno dei 24 progetti italiani selezionati. Il suo lavoro mira a dimostrare il valore clinico della tecnologia applicandola al cancro e alle malattie autoimmuni, identificando recettori specifici dei linfociti T che riconoscono antigeni tumorali e componenti dell'organismo nelle malattie autoimmuni. "Comprendere quali recettori riconoscono quali bersagli è fondamentale per sviluppare strumenti diagnostici più accurati, terapie personalizzate e nuovi vaccini", ha dichiarato Giulia Pasqual. La sua tecnologia innovativa, già validata su piccola scala, è protetta da una domanda di brevetto.

Generando e validando ampi insiemi di dati di rilevanza clinica, il progetto potrà fornire nuovi biomarcatori e nuove opportunità per lo sviluppo di terapie basate sul sistema immunitario. E parallelamente, verrà rafforzata la protezione della proprietà intellettuale e definita una strategia per un futuro sfruttamento commerciale. Nel complesso, il progetto può aprire nuove prospettive per la medicina di precisione e accelerare lo sviluppo di immunoterapie e vaccini terapeutici di nuova generazione.

Nel 2025, sono stati presentati 879 progetti alla Commissione, di cui 300 sono stati finanziati. L'Italia si è classificata al terzo posto per numero di finanziamenti ottenuti, con 31 grant.
"Le scoperte finanziate dall'ERC sono più di semplici progressi accademici", ha commentato Ekaterina Zaharieva, commissaria europea per le Startup, la Ricerca e l'Innovazione. "Costituiscono le fondamenta dei futuri ecosistemi dell'innovazione in tutta Europa".

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it

On the occasion of the Winter Olympic and Paralympic Games, a major free andrological prevention initiative kicks off in Cortina d’Ampezzo, offering medical check-ups, screenings and educational outreach to bring men’s health back to the forefront.
“No T to Lose” is an ambitious medical prevention and scientific awareness project that will run throughout the entire duration of the Olympic Games, from 6 February to 15 March 2026.

Promoted by the Veneto Region, the Padua University Hospital (AOUPD) and the University of Padua, with scientific coordination by Andrea Garolla, the initiative aims to raise awareness among the male population about the crucial importance of prevention in the field of andrology.

The project’s name plays on the letter “T”, which encompasses three fundamental concepts for men’s health: testicle, testosterone, and also time. These are key elements that are often overlooked, yet decisive for the early diagnosis of conditions that, if ignored, can compromise fertility, sexuality and overall well-being.

The beating heart of the initiative will be Cortina d’Ampezzo. During the competitions, residents, tourists and sports fans will be able to access clinics set up at the SISP (via Cesare Battisti 80, just steps from Corso Italia) to receive free medical check-ups and age-specific screenings.
For adolescents aged 14 to 18, the focus will be on pubertal development and the prevention of testicular cancer; for young adults (19–25), attention will be on fertility and sexually transmitted diseases; while for those over 50, the emphasis will be on prostate and metabolic prevention.

In addition to medical visits, the project will bring to life the Agora of Prevention: a meeting space where, every afternoon before the award ceremonies, doctors, researchers and well-known figures from sports and entertainment will take turns highlighting the importance of “playing ahead” against disease. Among the prominent supporters of the initiative is ski champion Kristian Ghedina, the project’s key testimonial. “In Italy, after the abolition of compulsory military medical examinations in 2005, the only form of mass screening for young men disappeared. Today we are witnessing a true gender gap in prevention: while girls are accustomed from a young age to gynecological check-ups, fewer than 5% of males under twenty have ever had an andrological examination. With ‘No T to Lose’, we want to reverse this trend precisely in the Olympic context, where the body and health are absolute protagonists. The ‘T’ in our slogan stands for Testicle and Testosterone, but above all for Time: because in medicine, as in sport, timing is everything, and early diagnosis is the real gold medal that can save lives,” commented Garolla.

For more information about the event schedule and to book free medical visits, please visit the official website: www.nottl.it